To read the full story, subscribe or sign in.

Junshi and Mabwell’s adalimumab biosimilar wins NMPA approval

March 8, 2022

Shanghai Junshi Biosciences Co. Ltd. and Mabwell Bioscience Co. Ltd. have won marketing approval for the adalimumab biosimilar Junmaikang from China’s NMPA for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis and psoriasis.

BioWorld Asia Regulatory

Today's news in brief

BioWorld

BioWorld briefs for Feb. 26, 2025.

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 26, 2025

Clots and metastasis in cancer patients start in the lung

BioWorld MedTech

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...